Sponsored by: Fujifilm

AIRS Medical secures investment funds from TA Associates

AuntMinnie.com staff writers
Jun 16, 2026

Medical imaging AI company AIRS Medical has received an investment from private equity firm TA Associates. 

Financial terms were not disclosed, but the funding will support global expansion and product development, according to an AIRS Medical announcement. 

The company's portfolio includes SwiftMR, an MRI acceleration and image enhancement solution, and SwiftSight, an MRI quantification and structured reporting platform. The AI-powered MRI acceleration and reconstruction software currently supports more than 1,700 healthcare institutions across 40 countries, the company said, adding that its technology is used in more than six million MRI exams annually.  

The transaction is expected to close in the second quarter of 2026.

AIRS Medical Inc.
Latest in MRI
The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails
Podcast: Update on state-level responses to Long Island MRI accident
June 16, 2026
Am 2019 02 20 20 38 9544 Mri Brain Head 400
MRI scans link poverty, not IQ, to children's brain differences
June 15, 2026
Bayer Rsna 2019 400
Bayer nets FDA approval for Ambelvist low-dose MRI contrast agent
June 15, 2026
Am 2016 10 04 11 38 34 158 Prostate 400
Experts propose new MRI standards for prostate cancer screening
June 11, 2026
Related Stories
Ai Handshake
MRI
SimonMed deploys AIRS Medical AI across its national MRI network
Ai Logo
MRI
AIRS Medical’s SwiftMR cleared to work alongside OEM AI tools
Airs Medical Am 400x300
Resources
Unlocking Smarter, Faster, Safer MRI with SwiftMR
The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails
MRI
Podcast: Update on state-level responses to Long Island MRI accident
More in MRI
Podcast: Update on state-level responses to Long Island MRI accident
By Liz Carey
As the McAllister story draws to a soft close, what's next?
June 16, 2026
The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails
MRI scans link poverty, not IQ, to children's brain differences
By Kate Madden Yee
Socioeconomic conditions leave the deepest imprint on brain function of any factor, researchers reported.
June 15, 2026
Am 2019 02 20 20 38 9544 Mri Brain Head 400
Bayer nets FDA approval for Ambelvist low-dose MRI contrast agent
By AuntMinnie.com staff writers
Bayer has received FDA approval for its macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI.
June 15, 2026
Bayer Rsna 2019 400
Experts propose new MRI standards for prostate cancer screening
By Kate Madden Yee
The guidance is intended to provide consensus on the acquisition, interpretation, and reporting of prostate MRI.
June 11, 2026
Am 2016 10 04 11 38 34 158 Prostate 400
AI gives a boost to cardiac MRI risk prediction
By Kate Madden Yee
Accurate risk prediction for coronary heart disease helps clinicians guide patient therapy and follow-up.
June 10, 2026
C-index for Cox regression and random survival forests models using two feature sets. Adding historical registry data decreases the C-index for Cox regression but increased it for the random survival forests model, consistent with the non-linear structure in the registry data.
fMRI reveals postmenopausal brain connectivity shifts in midlife women
By Kate Madden Yee
The findings suggest that menopause represents "an important neurological transition," researchers noted.
June 9, 2026
Network-level analysis comparing functional association strength between ROIs of pre- and postmenopausal groups. Lower levels of connectivity were identified among one cluster (F3,106 = 8.84, Puncorrected < 0.001, PFDR = 0.012) in the postmenopausal group, which included the right supramarginal gyrus anterior division, right planum temporale, and right Heschl’s gyrus, among others. FDR, false discovery rate; ROI, region of interest.
MRI finds perfusion defects across a range of lung impairments
By Kate Madden Yee
Impaired lung function is associated with increased pulmonary perfusion defects detectable by a particular MRI technique.
June 4, 2026
Caption: Representative images show emphysema and functional lung maps derived by CT and PREFUL-MRI: (A–C) CT-derived emphysema images, (D–F) perfusion maps, (G–I) regional ventilation maps, (J–L) flow-volume loop correlation metric maps, (M–O) ventilation/perfusion combined parameter maps. (A, D, G, J, M) Images in a 63-year-old male with normal spirometry: FEV1%pred = 89.0%, FEV1/FVC = 0.73; emphysema percentage = 0.2%, QDP = 7%, VDPRVent = 2%, VDPFVL-CM = 1%. (B, E, H, K, N) Images in a 65-year-old female with PRISm + RP: FEV1%pred = 71.2%, FVC %pred = 76.8%, FEV1/FVC = 0.76; emphysema percentage = 4.7%, QDP = 10%, VD-PRVent = 18%, VDPFVL-CM = 6%. (C, F, I, L, O) Images in a 57-year-old male with AO: FEV1%pred = 56.8%, FEV1/FVC = 0.52; emphysema = 11.1%, QDP = 31%, VDPRVent = 33%, VDPFVL-CM = 41%. AO = airflow obstruction, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, FVL-CM = flow-volume loop correlation metric, %pred = percent predicted, PREFUL = phase-resolved function lung, PRISm = preserved ratio impaired spirometry, QDP = perfusion defect percentage, RVent = regional ventilation, VDP = ventilation defect percentage.
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Podcast: Telltale signs your MRI safety standards are inadequate
By Liz Carey
Check your MRI safety sense.
June 2, 2026
The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails
ASCO: Surveillance MRI boosts breast cancer detection for Black women
By Erik L. Ridley
Surveillance breast MRI could potentially reduce persistent racial disparities in breast cancer outcomes, according to a study presented at ASCO 2026.
May 30, 2026
Asco Thumb
Eye movement abnormalities flag brain health risk in ex-racing drivers
By Kate Madden Yee
A case series of 12 male retired professional motorsport drivers showed a high prevalence of mild neurological abnormalities.
May 29, 2026
Racecare Thumb
Philips brings Disney characters to pediatric MRI ambient experience
By AuntMinnie.com staff writers
The integration uses calming lighting, sound, and visual elements alongside Disney content.
May 28, 2026
Ambient Experience for MRI platform with Disney characters
Page 1 of 645
Next Page